Loretta J Nastoupil
Overview
Explore the profile of Loretta J Nastoupil including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
185
Citations
5736
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nastoupil L, Bonner A, Wang P, Almuallem L, Desai J, Farazi T, et al.
Exp Hematol Oncol
. 2025 Mar;
14(1):30.
PMID: 40045329
Background: The treatment landscape for relapsed or refractory (R/R) follicular lymphoma (FL) has changed with the introduction of anti-CD19 chimeric antigen receptor T-cell therapies, including lisocabtagene maraleucel (liso-cel) and CD20...
2.
Nastoupil L, Andersen C, Ayers A, Wang Y, Habermann T, Chihara D, et al.
Clin Lymphoma Myeloma Leuk
. 2025 Feb;
PMID: 39966020
Introduction: Clinical trials provide meaningful data regarding the safety and efficacy of novel therapies but there is often a lag between the time of new drug approval and information on...
3.
Manzar G, Pinnix C, Dudzinski S, Marqueen K, Cha E, Nasr L, et al.
Front Immunol
. 2025 Feb;
16:1517348.
PMID: 39958356
Background: Select patients with relapsed/refractory aggressive B cell lymphoma may benefit from bridging radiation (bRT) prior to anti-CD19-directed chimeric antigen receptor T cell therapy (CAR-T). Here, we examined patient and...
4.
Yamshon S, Koff J, Larson M, Kahl B, Casulo C, Lossos I, et al.
Am J Hematol
. 2025 Feb;
100(4):606-615.
PMID: 39918101
Rituximab, gemcitabine, and oxaliplatin (R-GemOx) is a commonly used chemoimmunotherapy regimen for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but there are limited real-world data. In a multicenter...
5.
Chihara D, Steiner R, Nair R, Feng L, Ahmed S, Strati P, et al.
Blood Adv
. 2025 Feb;
PMID: 39908461
Treatment options are limited for both relapsed/refractory primary and secondary central nervous system (CNS) lymphoma and the prognosis remains poor. Prior studies have shown the activity of Bruton tyrosine kinase...
6.
Epperla N, Nastoupil L, Feinberg B, Galvin J, Pathak P, Amoloja T, et al.
Biomark Res
. 2025 Jan;
13(1):18.
PMID: 39849596
Potential CD19 antigen loss following CD19-directed therapy has raised concerns over sequential use of these therapies. Tafasitamab, a CD19-targeting immunotherapy, combined with lenalidomide, is approved for relapsed or refractory diffuse...
7.
Friedberg J, Brady M, Strawderman M, Kahl B, Lossos I, Cohen J, et al.
EClinicalMedicine
. 2024 Dec;
78:102959.
PMID: 39677358
Background: There is a significant association between low vitamin D levels at diagnosis of indolent B-cell lymphomas and inferior overall survival (OS). To determine whether supplemental vitamin D improves event-free...
8.
Riedell P, Grady C, Nastoupil L, Luna de Abia A, Luna A, Ahmed N, et al.
Blood Adv
. 2024 Dec;
9(5):1232-1241.
PMID: 39657136
Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed chimeric antigen receptor T-cell therapy approved for the treatment of relapsed/refractory large B-cell lymphoma. We present a multicenter retrospective study evaluating safety, efficacy,...
9.
Day J, Larson M, Durani U, Koff J, Wang Y, Habermann T, et al.
Blood Adv
. 2024 Nov;
9(5):1013-1023.
PMID: 39602301
Progression of disease within 24 months of initial immunochemotherapy (POD24) is a negative prognostic factor for patients with follicular lymphoma (FL). There is no standard treatment after POD24. Assembling an...
10.
Chong E, Penuel E, Napier E, Lundberg R, Budde L, Budde L, et al.
Blood Adv
. 2024 Nov;
9(4):696-703.
PMID: 39571171
Mosunetuzumab and other CD20/CD3 bispecific antibodies (BsAbs) have efficacy in B-cell lymphomas relapsing after or refractory to CD19-directed chimeric antigen receptor (CAR)-modified T cells (CAR-T). The optimal timing of BsAbs...